This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Gary Haynes, PhD, MD; Melinda K. Bailey, MD; Sharon Davis, PharmD; John E. Mahaffey, MD
Departments of Anesthesiology and Pharmacy Services Medical University of South Carolina 171 Ashley Ave Charleston, SC 29425-2207

Arch Neurol. 1989;46(11):1167-1168.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The warnings of methylprednisolone use in epidural analgesia by Dr Nelson¹ raises important issues for physicians caring for patients with chronic low-back pain. As he noted, there is no doubt that polyethylene glycol is neurotoxic, and is the likely cause for sterile meningitis when methylprednisolone is injected in the subarachnoid space. It is noteworthy that corticosteroids have not been approved for intrathecal use by the Food and Drug Administration. The package insert for methylprednisolone acetate (Depomedrol, Upjohn) states "not recommended" for subarachnoid injection.

A large body of clinical experience suggests the use of local anesthetics and steroids in the epidural space is a safe and effective treatment for the conservative management of low back pain in which there is reasonable evidence that inflammation of nerve roots is the cause of the symptoms. Two steroids, methylprednisolone acetate, 40 to 80 mg (Depomedrol, Upjohn), and triamcinolone diacetate . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?